Mark Seierstad

USPTO Granted Patents = 12 (Patent Applications = 5)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 7.3

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

San Diego, CA (US) (2008 - 2013)
Escondido, CA (US) (2013 - 2023)

Company Filing History:

10 out of 2,078

Janssen Pharmaceutica Nv

patents

1 out of 1

Jannsen Pharmaceutica Bv

patent

1 out of 13

Johnson & Johnson Pharmaceutical Research & Development, LLC

patents

Years Active: 2008-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11827638 - Imidazopyrrolopyridine as inhibitors of the JAK family of kinases (2023-11-28),

2. 10981911 - Imidazopyrrolopyridine as inhibitors of the JAK family of kinases (2021-04-20),

3. 9169224 - Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase (2015-10-27),

4. 8906914 - Ethylene diamine modulators of fatty acid hydrolase (2014-12-09),

5. 8598356 - Heteroaryl-substituted urea modulators of fatty acid amide hydrolase (2013-12-03),

6. 8598202 - Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase (2013-12-03),

7. 8530476 - Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase (2013-09-10),

8. 8461159 - Heteroaryl-substituted urea modulators of fatty acid amide hydrolase (2013-06-11),

9. 8183239 - Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor (2012-05-22),

10. 7598249 - Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase (2009-10-06),

11. 7541359 - N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase (2009-06-02),

12. 7317025 - Non-peptidic NPY Y2 receptor inhibitors (2008-01-08),

Hello! I'm glad to assist you with the article about the innovative inventor Mark Seierstad.

Title: Mark Seierstad: Revolutionizing Healthcare with Innovative Pharmaceutical Patents

Introduction: Mark Seierstad, a talented inventor based in Escondido, CA, has shown exceptional prowess in the field of pharmaceutical inventions. With a total of 12 patents to his name, his contributions to the healthcare industry are truly remarkable.

Latest Patents: Mark Seierstad’s latest patents involve the groundbreaking development of Imidazopyrrolopyridine as inhibitors of the JAK family of kinases. These compounds and pharmaceutical compositions exhibit significant potential in treating various diseases and conditions mediated by JAK, including inflammatory bowel disease.

Career Highlights: Mark Seierstad has leveraged his expertise while working with prestigious pharmaceutical companies such as Janssen Pharmaceutica N.V and Janssen Pharmaceutica B.V. His innovative approach and dedication have played a pivotal role in advancing the pharmaceutical landscape.

Collaborations: Throughout his career, Mark has collaborated with accomplished professionals in the field, including J Guy Breitenbucher and Richard Apodaca. These collaborations have fostered a vibrant environment for ideation and innovation.

Conclusion: In conclusion, Mark Seierstad's relentless pursuit of innovation in pharmaceuticals underscores his commitment to improving healthcare outcomes. His inventive spirit and collaborative efforts continue to shape the future of medicine, making him a notable figure in the realm of pharmaceutical inventions.

Feel free to reach out if you need more information or assistance!

This text is generated by artificial intelligence and may not be accurate.